Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.

about

Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.

Item

http://www.wikidata.org/entity/Q52655141

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Targeted sequencing reveals di ...... enocarcinoma brain metastases.

@en

Targeted sequencing reveals di ...... enocarcinoma brain metastases.

@nl

type

Item

label

Targeted sequencing reveals di ...... enocarcinoma brain metastases.

@en

Targeted sequencing reveals di ...... enocarcinoma brain metastases.

@nl

prefLabel

Targeted sequencing reveals di ...... enocarcinoma brain metastases.

@en

Targeted sequencing reveals di ...... enocarcinoma brain metastases.

@nl

P1476

Targeted sequencing reveals di ...... enocarcinoma brain metastases.

@en

P2093

Kun Chen

http://www.w3.org/2001/XMLSchema#string

Ming Guan

http://www.w3.org/2001/XMLSchema#string

Yanchun Ma

http://www.w3.org/2001/XMLSchema#string

Zhenhua Yang

http://www.w3.org/2001/XMLSchema#string

P2860

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Global cancer statistics, 2012

Comprehensive molecular profiling of lung adenocarcinoma.

Whole-genome analysis informs breast cancer response to aromatase inhibition

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

P304

4503-4510

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2018.7859

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29541220

http://www.w3.org/2001/XMLSchema#string

P932

5835849

http://www.w3.org/2001/XMLSchema#string